Estrella Immunopharma (ESLA) announced that the company has regained compliance with the listing requirements of Nasdaq. This confirmation follows the company’s efforts to improve its balance sheet, including raising new capital to continue development of its therapeutic candidates.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ESLA: